nodes	percent_of_prediction	percent_of_DWPC	metapath
Furazolidone—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.379	0.379	CbGpPWpGaD
Furazolidone—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.301	0.301	CbGpPWpGaD
Furazolidone—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.173	0.173	CbGpPWpGaD
Furazolidone—MAOB—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.0934	0.0934	CbGpPWpGaD
Furazolidone—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0132	0.0132	CbGpPWpGaD
Furazolidone—MAOB—Metabolism—HDC—Gilles de la Tourette syndrome	0.0116	0.0116	CbGpPWpGaD
Furazolidone—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.0111	0.0111	CbGpPWpGaD
Furazolidone—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.0101	0.0101	CbGpPWpGaD
Furazolidone—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.00731	0.00731	CbGpPWpGaD
